The Deep Lens VIPER platform has integrated molecular data parsing and management technology. The integration is designed to empower cancer care teams, trial sponsors and coordinators to rapidly match patients, based on the genetic profile of their cancer, to the appropriate therapies and oncology trials.
The company’s partnerships on the technology includes the University of Miami Office of Technology Transfer, who worked with Deep Lense to license the technology.
“Our office facilitates transfer of university innovations for the benefit of the university community and the public,” said Bin Yan, director of the Office of Technology Transfer. “It was a natural fit to work with Deep Lens and integrate our two differentiated technologies to solve a real problem in clinical trial recruitment: limited time and resources for physicians and care teams.”
Additionally, a team from Sylvester Comprehensive Cancer Center (part of the University of Miami Miller School of Medicine) and UHealth Information Technology developed an engine to leverage new ways of consuming and normalizing molecular genetic test results from companies, such as Caris Life Sciences, Foundation Medicine, Guardant Health, NeoGenomics, Tempus, and more, to automate and expedite the patient screening process.
Previously, genetic test results were sent to healthcare providers, where a trained specialist or physician would analyze the results for therapy decisions. However, according to the company, trial coordinators frequently have no access to such data, nor do they have the ability to extract information from it when matching patients to clinical trials, leading to inconsistencies in the screening process and missed opportunities to leverage the data.
According to Deep Lens, integrating this data into the VIPER platform, enables molecular test results from any lab vendor, across all patients, to be quickly searched and easily analyzed by cancer care teams and clinical trial coordinators. This makes it possible to automatically match patients to the best precision-based clinical trials available.
Jim Langford, vice president of clinical operations for Irvine-CA-based Aivita Biomedical, said the automated patient matching builds upon previous improvements to the patient screening process.
“With the addition of automated molecular-based patient matching, we see VIPER giving us much greater granularity into how we work with our provider sites to drive greater patient engagement,” he said.
Deep Lens co-founder and chief scientist TJ Bowen said the partnership between his company and University of Miami researchers will lead to a longtime, mutually beneficial collaboration.
“Integrating this molecular data parsing and management technology into VIPER and continuing to work with University of Miami on integrating future genomics advancements will ensure that we have the leading and most up-to-date information and technologies,” Bowen said. “Now, cancer care teams, clinical trial sponsors, and trial coordinators can leverage an AI-enabled workflow platform that aggregates all relevant data sources for even faster automation and improved patient matching to increase clinical trial enrollment.”
